First Approvals Under EMA’s Adaptive Pathways May Be Just A Few Years Away
Executive Summary
The first marketing authorizations under the European Medicines Agency’s hotly debated adaptive pathways concept for getting drugs to patients faster could be granted in just a few years’ time.
You may also be interested in...
EU HTA Bodies, Payers Look At Ways To Fill Evidence Gaps In Early Access Schemes
While the German pricing and reimbursement authority continues to argue that there is insufficient comparative data for drugs that are granted conditional marketing authorization, health technology assessment bodies and payers in the EU generally agree that they need to find innovative solutions to work around these evidence gaps.
EMA Defends Adaptive Pathways Against Fresh Attack Following Pilot Report
The European Medicines Agency has dismissed a call to stop accepting applications for its adaptive pathways program until it has better evidence on how to use real-world data.
Adaptive Pathways: Companies Advised To Consider Hurdles As EMA Accepts More Applications
The European Medicines Agency has released its keenly awaited final report on it adaptive pathways pilot and says it will continue to accept applications for the new drug development concept. Meanwhile, law firm Bristows highlights the hurdles ahead for applicants.